Cathepsin D plays a role in endothelial–pericyte interactions during alteration of the blood–retinal barrier in diabetic retinopathy
Authors:
Open Access
- 20 December 2017
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 32 (5) , 2539-2548
Abstract
Inflammation plays an important role in the pathogenesis of diabetic retinopathy. We have previously demonstrated the effect of cathepsin D (CD) on the mechanical disruption of retinal endothelial cell junctions and increased vasopermeability, as well as increased levels of CD in retinas of diabetic mice. Here, we have also examined the effect of CD on endothelial‐pericyte interactions, as well as the effect of dipeptidyl peptidase‐4 (DPP4) inhibitor on CD in endothelial‐pericyte interactions in vitro and in vivo. Cocultured cells that were treated with proCD demonstrated a significant decrease in the expression of platelet‐derived growth factor receptor‐β, a tyrosine kinase receptor that is required for pericyte cell survival; N‐cadherin, the key adherens junction protein between endothelium and pericytes; and increases in the vessel destabilizing agent, angiopoietin‐2. The effect was reversed in cells that were treated with DPP4 inhibitor along with pro‐CD. With pro‐CD treatment, there was a significant increase in the phosphorylation of the downstream signaling protein, PKC‐α, and Ca 2+ /calmodulin‐dependent protein kinase II in endothelial cells and pericytes, which disrupts adherens junction structure and function, and this was significantly reduced with DPP4 inhibitor treatment. Increased CD levels, vasopermeability, and alteration in junctional‐related proteins were observed in the retinas of diabetic rats, which were significantly changed with DPP4 inhibitor treatment. Thus, DPP4 inhibitors may be used as potential adjuvant therapeutic agents to treat increased vascular leakage observed in patients with diabetic macular edema.—Monickaraj, F., McGuire, P., Das, A. Cathepsin D plays a role in endothelial‐pericyte interactions during alteration of the blood‐retinal barrier in diabetic retinopathy. FASEB J. 32, 2539–2548 (2018). www.fasebj.orgKeywords
Funding Information
- National Institutes of Health (R01‐EY022327)
This publication has 59 references indexed in Scilit:
- Update on animal models of diabetic retinopathy: from molecular approaches to mice and higher mammalsDisease Models & Mechanisms, 2012
- The role of ADAM-mediated shedding in vascular biologyEuropean Journal of Cell Biology, 2012
- Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in ratsJournal of Biomedical Research, 2012
- Role of inflammation in the pathogenesis of diabetic retinopathyMiddle East African Journal of Ophthalmology, 2012
- Pericyte-Derived Sphinogosine 1-Phosphate Induces the Expression of Adhesion Proteins and Modulates the Retinal Endothelial Cell BarrierArteriosclerosis, Thrombosis, and Vascular Biology, 2011
- Diabetic Nephropathy Amelioration by a Low-Dose Sitagliptin in an Animal Model of Type 2 Diabetes (Zucker Diabetic Fatty Rat)Experimental Diabetes Research, 2011
- Inflammation in diabetic retinopathyProgress in Retinal and Eye Research, 2011
- A Potential Role for Angiopoietin 2 in the Regulation of the Blood–Retinal Barrier in Diabetic RetinopathyInvestigative Ophthalmology & Visual Science, 2011
- The role of adherens junctions and VE-cadherin in the control of vascular permeabilityJournal of Cell Science, 2008
- RICS, a Novel GTPase-activating Protein for Cdc42 and Rac1, Is Involved in the β-Catenin-N-cadherin andN-Methyl-d-aspartate Receptor SignalingJournal of Biological Chemistry, 2003